Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06992115 · ClinicalTrials.gov registry record · NA

A Study of the MIND Diet for Persons With Multiple Sclerosis

A NA study of Multiple Sclerosis, sponsored by Icahn School of Medicine at Mount Sinai.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT06992115: Recruiting NA study of Multiple Sclerosis, sponsored by Icahn School of Medicine at Mount Sinai.

NCT06992115 is a NA study of Multiple Sclerosis that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 100 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06992115, a NA study of Multiple Sclerosis, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

This study will assess the impact of a MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay) diet on brain health and MS symptoms. Participants will be randomly assigned to one of two arms: the diet intervention arm or the "continue current diet"/control arm. Participants randomized to the dietary intervention arm will change their diet to follow a MIND dietary pattern for one year; diet-related education and programming is provided to support this change. Participants randomized to the continue/control arm will be asked to continue their current dietary habits, without major change for one year; multiple sclerosis (MS) MS-related related education and programming (unrelated to diet) is provided. All participants will be asked to provide blood \& stool samples and to complete online questionnaires \& three in-person assessments.

Primary Outcome

Plasma NfL quantification will be reported in units of pg/ml.

Conditions Studied

Interventions

  • BEHAVIORAL Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet
  • BEHAVIORAL Small Group

Study Locations (1)

New York

  • Mount Sinai Hospital - New York

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-05-12
Est. Completion 2029-04-30
Phase NA

What NCT06992115 shows while recruiting

NCT06992115 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (83% lower).

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet is the first listed.

NCT06992115 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT06992115 about?

NCT06992115 is a clinical study titled "A Study of the MIND Diet for Persons With Multiple Sclerosis". This study will assess the impact of a MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay) diet on brain health and MS symptoms. Participants will be randomly assigned to one of two arms: the diet intervention arm or the "continue current diet"/control arm. Participants randomized to ...

What is the current status of trial NCT06992115?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2025-05-12. Estimated completion is 2029-04-30.

What conditions does trial NCT06992115 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

What interventions are being tested in trial NCT06992115?

The interventions under investigation include: Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet (BEHAVIORAL), Small Group (BEHAVIORAL).

Who is sponsoring clinical trial NCT06992115?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06992115 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06992115's enrollment target sits among peer trials

100 128th of 315 higher than 181 of 315 other Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06992115, the US trial registry maintained by the National Library of Medicine. NCT06992115 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.